Before a single patient can receive ERNA-101, someone has to make it, and make it to a standard regulators accept. On May 27, Ernexa Therapeutics said it had cleared that hurdle.
The Cambridge, Massachusetts company announced it had finished process development for the manufacturing of ERNA-101, its lead cell therapy, and moved into Good Manufacturing Practice production in preparation for clinical use. Technology transfer was running in parallel. The company kept to its target of filing an Investigational New Drug application, the formal request to begin human testing, in the third quarter of 2026.
“We are executing against our development strategy with urgency and discipline,” said chief executive Sanjeev Luther, who added that the company believes ERNA-101 “has the potential to bring new hope to patients and families in need of better therapeutic options.”
What came before
The manufacturing news followed a regulatory step. In early February, Ernexa described a successful pre-IND meeting with the US Food and Drug Administration. Luther said the FDA’s alignment on the development strategy gave the company a clear path to file and to begin clinical testing in the second half of 2026.
By March 31 the company had gone further, listing proof-of-principle studies finished for ERNA-101 and for a second candidate, ERNA-201. It also reported a recent $10.5 million financing and general and administrative expenses down about 61% year over year. Its schedule then called for the first product batch to be released in the third quarter, along with the IND filing.
The therapy and the target
ERNA-101 is built from engineered synthetic induced mesenchymal stem cells made from induced pluripotent stem cells, designed to deliver immune-activating cytokines inside tumours and turn immunologically “cold” tumours into ones the immune system can respond to. The first target is platinum-resistant ovarian cancer. In a syngeneic ovarian cancer model, the company said, ERNA-101 combined with an anti-PD-1 antibody produced durable antitumour activity and high rates of complete regression, a stronger result than either agent alone.
Animal results are not a promise for patients, and anyone facing this diagnosis should keep to the treatment plan agreed with their doctor. The company’s own timetable puts the first human dosing in the fourth quarter of 2026, with first clinical data not expected until the first half of 2027.
Sources
- Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
- Ernexa Therapeutics Advances toward First-in-Human Trial for Ovarian Cancer Following Successful Pre-IND Meeting with FDA | ERNA Stock News
- Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
